Skip to content
value.today

Curve Biosciences, Inc.

Formerly Canary Biosciences, Inc.

Total raised
$18 M
1 round on record
Latest round
$18 M
May 2024
First round on record
May 2024
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Curve Biosciences, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2024$18 MNo. 1$10 to $50 million

Curve Biosciences, Inc.: Raise no. 1, May 2024

Investors in this round

64 investors had bought by the notice of May 13, 2024: 64 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$18 M of $20 M offered; $2 M still to sell
Smallest investment taken
$1
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Chuba Oyolu · Executive Officer
  • Nathan Hunkapiller · Executive Officer
  • Ritish Patnaik · Executive Officer, Director
  • Shan Xiang Wang · Executive Officer, Director
  • Themasap Khan · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Ritish Patnaik, Chief Executive Officer. Newest notice filed May 13, 2024. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Curve Biosciences, Inc. chose not to state its revenue in its newest notice of a funding round (May 2024).

    SEC Form D · May 2024

  • The industry group it chose in its notices: Other.

    SEC Form D · May 2024

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Curve Biosciences, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Curve Biosciences, Inc.
NameRoleNamed in
Chuba OyoluExecutive officerMay 2024
Nathan HunkapillerExecutive officerMay 2024
Ritish PatnaikExecutive officerMay 2024
Shan Xiang WangExecutive officerMay 2024
Ritish PatnaikDirectorMay 2024
Shan Xiang WangDirectorMay 2024
Themasap KhanDirectorMay 2024